Under the deal, French fine chemicals maker PCAS will produce foscarnet sodium hexahydrate – the API (active pharmaceutical ingredient) in Foscavir, which treats HIV/AIDS related cytomegalovirus (CMV) infections and herpes.
Clinigen, which holds the marketing authorisations for the medicine, will continue to distribute the product in 16 countries worldwide.
The British firm is currently trying to gain approval for additional markets, including the US in Q1 2012.
Anton Jenkins, Chief Operating Officer of Clinigen Healthcare, commented: “PCAS has an impeccable track record in the area of API manufacturing, with strong technical capabilities and robust compliance systems, making the company an ideal partner for Clinigen.”